Epidemiology of mucormycosis in Europe

Abstract

Zygomycosis (mucormycosis) is being increasingly recognized as causing infection in recent years. National and multinational European surveys attempting to analyse the epidemiological parameters of this potentially devastating infection are very few. Although the exact incidence could not be defined due to the different methodologies used in these studies and the absence of a denominator, there were some useful observations made regarding the clinical presentation, sites of infection and diagnostic practices. Moreover, the importance for a prompt and accurate diagnosis has been stressed. As early diagnosis can significantly affect the initiation of treatment and decrease mortality, future research should focus on the development of an epidemiological risk assessment tool and novel diagnostic methods.

Multicenter Evaluation of MIC Distributions for Epidemiologic Cutoff Value Definition To Detect Amphotericin B, Posaconazole, and Itraconazole Resistance among the Most Clinically Relevant Species of Mucorales

“…For these molds and antifungal agents, correlations between MICs and clinical response to therapy were not found in the literature, even though large numbers of mucormycosis cases have been reported. To compound the problem, cultures are not always available, since other methods of diagnosis are usually performed to promptly initiate therapy, e.g., histopathology (5,31). Outcome is also influenced by the site of infection, the underlying disease, and other factors.…”

Hospital days, hospitalization costs, and inpatient mortality among patients with mucormycosis: a retrospective analysis of US hospital discharge data

“…Between 2001 and 2005, analyses of data from the Transplant Associated Infections Surveillance Network (TRANSNET), showed that mucormycosis represented 8% and 2% of IFIs found in patients receiving hematopoietic stem cell and solid organ transplant recipients, respectively [6,7]. More recent publications from Europe and Asia highlight the increasing recognition of mucormycosis around the globe, and also present data supporting a shift from such traditional risk factors, with hematological malignancies as the most common underlying condition [8-10]. …”

MUCORMYCOSIS IN ONCOHEMATOLOGY PATIENTS (results of the prospective study)

“…Результаты нашего исследования, а также данные литературы свидетельствуют, что у онкогематологиче-ских больных наиболее частой клинической формой мукормикоза является поражение легких (50-81 %) [2,[11][12][13]. В то же время у детей чаще развивается риноцеребральный мукормикоз (29 % vs 8 %).…”

“…Одной из таких инфекций является мукормикоз. Следует отметить, что рост распространенности мукормикоза у онкогематологических больных отмечен во всем мире, и именно острые лейкозы становятся основным фоновым заболеванием для данной инфекции в раз-витых странах [2]. В иссследовании, проведенном в 2009 г.…”

“…В настоящее время особенности течения мукор-микоза у онкогематологических больных представле-ны на основании изучения небольших когорт боль-ных [2].…”